froggmister,
No one is absolutely sure that it was referred back to CHM. Even exwannabe understands that this is not necessarily what has happened. My perspective has been focused on clues from what is going on with manufacturing because of the expected impact and demand all the news that we have seen about L will bring. What happens when the improvements made with Poly ICLC, the patent with the combos, the manufacturing changeover being anticipated, the cancer designation for the NHS high priced medicines list which goes beyond GBM and rGBM for IFRs, the need of Merck and others to extend patent protection with their checkpoint inhibitors etc. get made known to the general public and cancer patients want access? Everyone needs to be ready and being ready takes time and money.
MHRA can ask all the questions they want in order for everyone to be ready and they can clock off all they want too. We saw exwannabe acknowledge this because nobody can hold MHRA accountable to a specific time frame nor will they do so themselves as long as they see the kind of progress being made they want to see.
The clues all point to a common desire to see Flaskworks properly positioned to take on ALL of the future demand capacity past the current artisan method clean room space and I expect questions and answers to come between MHRA and NWBO as sentiment_stocks implies until all pertinent parties are satisfied that will be the case. Maybe we should call it the MAA ballet; ). Best wishes.
AI
Market Data 
Markets 
